Merck & Co., Inc. $MRK Stock Bought by Signaturefd LLC

Signaturefd LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,332 shares of the company’s stock after buying an additional 4,208 shares during the quarter. Signaturefd LLC’s holdings in Merck & Co., Inc. were worth $8,912,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in MRK. Dimensional Fund Advisors LP raised its stake in shares of Merck & Co., Inc. by 23.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Bank of America Corp DE boosted its position in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Diamant Asset Management Inc. boosted its position in shares of Merck & Co., Inc. by 12,130.3% during the 1st quarter. Diamant Asset Management Inc. now owns 2,068,387 shares of the company’s stock worth $248,806,000 after purchasing an additional 2,051,475 shares during the period. Assenagon Asset Management S.A. increased its holdings in Merck & Co., Inc. by 263.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock valued at $347,334,000 after purchasing an additional 1,959,778 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.4%

Shares of MRK opened at $145.25 on Friday. The company’s 50-day simple moving average is $146.98 and its 200-day simple moving average is $130.17. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The stock has a market capitalization of $358.35 billion, a PE ratio of 116.20, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts forecast that Merck & Co., Inc. will post 2.64 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on MRK shares. Morgan Stanley cut their target price on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Royal Bank Of Canada lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research report on Monday, October 12th. Berenberg Bank lifted their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Cantor Fitzgerald lifted their price objective on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, October 5th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Williams sold 52,847 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last three months. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.